WO2000020447A3 - Polynucleotides coding for secreted polypeptides, some having similarity to syncollin or claudin or cytokine, their therapeutic uses - Google Patents

Polynucleotides coding for secreted polypeptides, some having similarity to syncollin or claudin or cytokine, their therapeutic uses Download PDF

Info

Publication number
WO2000020447A3
WO2000020447A3 PCT/US1999/023294 US9923294W WO0020447A3 WO 2000020447 A3 WO2000020447 A3 WO 2000020447A3 US 9923294 W US9923294 W US 9923294W WO 0020447 A3 WO0020447 A3 WO 0020447A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
syncollin
claudin
protein
activity
Prior art date
Application number
PCT/US1999/023294
Other languages
French (fr)
Other versions
WO2000020447A8 (en
WO2000020447A2 (en
Inventor
Richard A Shimkets
Original Assignee
Curagen Corp
Richard A Shimkets
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curagen Corp, Richard A Shimkets filed Critical Curagen Corp
Priority to AU64170/99A priority Critical patent/AU766279B2/en
Priority to CA002345377A priority patent/CA2345377A1/en
Priority to JP2000574558A priority patent/JP2004500011A/en
Priority to EP99951812A priority patent/EP1119620A2/en
Publication of WO2000020447A2 publication Critical patent/WO2000020447A2/en
Publication of WO2000020447A3 publication Critical patent/WO2000020447A3/en
Publication of WO2000020447A8 publication Critical patent/WO2000020447A8/en
Priority to HK02100720.5A priority patent/HK1039783A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)

Abstract

The present invention provides novel isolated polypeptides chosen from among a) a syncollin-like protein having a syncollin-like activity; b) a novel polypeptide whose amino acid sequence is given by or is similar to SEQ ID NO:6; c) a claudin-like protein having a claudin-like activity; d) a cytokine-like protein whose amino acid sequence has at least 80 % identity to human GRO-beta and having a GRO-beta-like activity, and e) a fragment of any of them; as well as polynucleotides encoding them and antibodies that immunospecifically bind to them. The invention additionally provides several methods in which these proteins, polynucleotides and antibodies are used in methods of detection and methods of treatment are also disclosed. These methods additionally include methods employing proteins, polynucleotides and antibodies related to the additional substances a cysteine-rich soluble protein, and a mammaglobin homologue/endometrial specific steroid-binding factor III. These methods of detection and treatment are directed to a broad range of pathological states.
PCT/US1999/023294 1998-10-06 1999-10-06 Polynucleotides coding for secreted polypeptides, some having similarity to syncollin or claudin or cytokine, their therapeutic uses WO2000020447A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU64170/99A AU766279B2 (en) 1998-10-06 1999-10-06 Novel secreted proteins and polynucleotides encoding them
CA002345377A CA2345377A1 (en) 1998-10-06 1999-10-06 Novel secreted proteins and polynucleotides encoding them
JP2000574558A JP2004500011A (en) 1998-10-06 1999-10-06 Novel secreted protein and polynucleotide encoding the same
EP99951812A EP1119620A2 (en) 1998-10-06 1999-10-06 Polynucleotides coding for secreted polypeptides. some having similarity to syncollin or claudin or cytokine. their therapeutic uses
HK02100720.5A HK1039783A1 (en) 1998-10-06 2002-01-30 Polynucleotides coding for secreted polypeptides. some having similarity to syncollin or claudin or cytokine. their therapeutic uses

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10319598P 1998-10-06 1998-10-06
US60/103,195 1998-10-06
US41223199A 1999-10-05 1999-10-05
US09/412,231 1999-10-05

Publications (3)

Publication Number Publication Date
WO2000020447A2 WO2000020447A2 (en) 2000-04-13
WO2000020447A3 true WO2000020447A3 (en) 2000-09-28
WO2000020447A8 WO2000020447A8 (en) 2001-03-08

Family

ID=26800175

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/023294 WO2000020447A2 (en) 1998-10-06 1999-10-06 Polynucleotides coding for secreted polypeptides, some having similarity to syncollin or claudin or cytokine, their therapeutic uses

Country Status (6)

Country Link
EP (1) EP1119620A2 (en)
JP (1) JP2004500011A (en)
AU (1) AU766279B2 (en)
CA (1) CA2345377A1 (en)
HK (1) HK1039783A1 (en)
WO (1) WO2000020447A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7014996B1 (en) 1998-10-02 2006-03-21 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating gynecologic cancers
ATE525390T1 (en) * 1999-04-27 2011-10-15 Univ Pennsylvania USE OF RESISTANT SPECIFIC ANTIBODIES IN THE TREATMENT OF DIABETES
DE60128701T2 (en) * 2000-08-15 2008-02-07 Immunex Corp., Thousand Oaks CLAUDIN POLYPEPTIDE
US7186802B2 (en) 2000-08-15 2007-03-06 Immunex Corporation Claudin polypeptides
WO2002068649A2 (en) * 2001-01-31 2002-09-06 Curagen Corporation Proteins and nucleic acids encoding same
US7109302B1 (en) 2002-04-01 2006-09-19 Human Genome Sciences, Inc. Antibodies that specifically bind to GMAD
DE10254601A1 (en) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Gene products differentially expressed in tumors and their use
EP1431763A1 (en) * 2002-12-20 2004-06-23 BioVisioN AG Method for detecting a metabolic disease
DE102004024617A1 (en) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentially expressed in tumors gene products and their use
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2013174404A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
AU2013347184B2 (en) 2012-11-13 2018-06-14 Astellas Pharma Inc. Agents for treatment of claudin expressing cancer diseases
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014146672A1 (en) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997007198A2 (en) * 1995-08-11 1997-02-27 Genetics Institute, Inc. Dna sequences and secreted proteins encoded thereby
WO1997034997A1 (en) * 1996-03-21 1997-09-25 Human Genome Sciences, Inc. Human endometrial specific steroid-binding factor i, ii and iii
WO1998025959A2 (en) * 1996-12-11 1998-06-18 Chiron Corporation Secreted human proteins
WO1999054446A2 (en) * 1998-04-19 1999-10-28 Metagen Gesellschaft Für Genomforschung Mbh Human nucleic acid sequences which are overexpressed in normal pancreas tissue

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997007198A2 (en) * 1995-08-11 1997-02-27 Genetics Institute, Inc. Dna sequences and secreted proteins encoded thereby
WO1997034997A1 (en) * 1996-03-21 1997-09-25 Human Genome Sciences, Inc. Human endometrial specific steroid-binding factor i, ii and iii
WO1998025959A2 (en) * 1996-12-11 1998-06-18 Chiron Corporation Secreted human proteins
WO1999054446A2 (en) * 1998-04-19 1999-10-28 Metagen Gesellschaft Für Genomforschung Mbh Human nucleic acid sequences which are overexpressed in normal pancreas tissue

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GENOMICS, vol. 54, no. 1, 15 November 1998 (1998-11-15), pages 70 - 78 *
J.M. EDWARDSON ET AL: "The secretory granule protein Syncollin binds to Syntaxin in a Ca2+-sensitive manner", CELL, vol. 90, 25 July 1997 (1997-07-25), CELL PRESS, CAMBRIDGE, NA., US, pages 325 - 333, XP002133974, ISSN: 0092-8674 *
NCI-CGAP: "aj29d01.s1 Soares_testis_NHT Homo sapiens cDNA clone 1391713 3', mRNA sequence", EMBL DATABASE ENTRY AA824393, ACCESSION NUMBER AA824393, 20 February 1998 (1998-02-20), XP002133975 *
R.M. BECKER ET AL: "Identification of mammoglobin B, a novel member of the uteroglobin gene family", EMBL DATABASE ENTRY AF071219, ACCESSION NUMBER AF071219, 7 July 1998 (1998-07-07), XP002133976 *

Also Published As

Publication number Publication date
AU766279B2 (en) 2003-10-16
EP1119620A2 (en) 2001-08-01
CA2345377A1 (en) 2000-04-13
HK1039783A1 (en) 2002-05-10
WO2000020447A8 (en) 2001-03-08
WO2000020447A2 (en) 2000-04-13
JP2004500011A (en) 2004-01-08
AU6417099A (en) 2000-04-26

Similar Documents

Publication Publication Date Title
WO2000020447A3 (en) Polynucleotides coding for secreted polypeptides, some having similarity to syncollin or claudin or cytokine, their therapeutic uses
BG64881B2 (en) Tnf-binding proteins
CA2380690A1 (en) Human osteoclast-derived cathepsin
WO2001059064A3 (en) Nucleic acids, proteins, and antibodies
PT93910A (en) A product for the preparation of a blood protein by means of a blood cell
NZ279963A (en) Human tissue inhibitor of metalloproteinase-4 (timp-4) and dna (rna) encoding polypeptide which may be derived from atcc 75946
WO2002050277A3 (en) Protein and nucleic acids encoding same
WO1998022499A3 (en) Arretin, a neurite outgrowth modulator, antibodies thereto and uses thereof
WO2003080856A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2000026244A3 (en) A novel tumor necrosis factor family member, drl, and related compositions and methods
CA2230111A1 (en) Antisecretory factor peptides regulating pathological permeability changes
AU1239997A (en) Polypeptides corresponding to the amino acid sequences of proteins p57 or p9.5 of Borna disease virus, nucleic acid fragments coding therefore and their use for diagnostic and immunization purposes
WO2003029423A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO1996021020A3 (en) Borna disease viral sequences, diagnostics and therapeutics for nervous system diseases
WO2003031571A3 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
WO2000059942A3 (en) Human obesity protein binding protrein-2 homolog and uses thereof
AU2676399A (en) Novel cystine knot protein and materials and methods for making it
WO2003085124A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
DE69634994D1 (en) BOND WEAVE GROWTH FACTOR 3.
WO2001074897A3 (en) Protein amf-1 to amf-10 and nucleic acids encoding the same
WO2003033675A3 (en) Identification of binding partners for specific proteins
WO1999031256A3 (en) Cathepsin dc proteins, dna encoding the proteins, and their use in human cancer prognosis
WO2003064589A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2003004617A3 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
WO2003050245A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 1999 64170

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 15/2000 UNDER (30) REPLACE "NOT FURNISHED" BY "09/412231"

ENP Entry into the national phase

Ref document number: 2345377

Country of ref document: CA

Ref country code: CA

Ref document number: 2345377

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 574558

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 64170/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999951812

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999951812

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 64170/99

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1999951812

Country of ref document: EP